Barbara MacGregor‐Cortelli

Phase II Clinical Experience With the Novel Proteasome Inhibitor Bortezomib in Patients With Indolent Non-Hodgkin's Lymphoma and Mantle Cell Lymphoma

Owen A. O’Connor, Craig H. Moskowitz, Jamie Muzzy et al. · Journal of Clinical Oncology · 2004 · 579 citations

Medicine, Hematology, Pharmacology +17

Clinical Experience With Intravenous and Oral Formulations of the Novel Histone Deacetylase Inhibitor Suberoylanilide Hydroxamic Acid in Patients With Advanced Hematologic Malignancies

Owen A. O’Connor, Mark Heaney, Lawrence B. Schwartz et al. · Journal of Clinical Oncology · 2005 · 403 citations

Medicine, Hematology, Pharmacology +17

Phase II-I-II Study of Two Different Doses and Schedules of Pralatrexate, a High-Affinity Substrate for the Reduced Folate Carrier, in Patients With Relapsed or Refractory Lymphoma Reveals Marked Activity in T-Cell Malignancies

Owen A. O’Connor, Steven M. Horwitz, Paul A. Hamlin et al. · Journal of Clinical Oncology · 2009 · 183 citations

Medicine, Pharmacology, Pharmacotherapy +17

Pralatrexate, a novel class of antifol with high affinity for the reduced folate carrier‐type 1, produces marked complete and durable remissions in a diversity of chemotherapy refractory cases of T‐cell lymphoma

Owen A. O’Connor, Paul A. Hamlin, Carol S. Portlock et al. · British Journal of Haematology · 2007 · 92 citations

Medicine, Pharmacology, Pharmacotherapy +16

Drug‐induced cutaneous vasculitis in patients with non‐Hodgkin lymphoma treated with the novel proteasome inhibitor bortezomib: a possible surrogate marker of response?

John F. Gerecitano, André Goy, Barbara MacGregor‐Cortelli et al. · British Journal of Haematology · 2006 · 54 citations · Full text

Medicine, Dermatology, Pharmacology +14